Subsequently, after further structure–activity studies, a second generation chimera, BIM-23B065, was produced with significantly greater potency and efficacy than BIM-23A760, as demonstrated by suppression of GH secretion from primary cultures of human GH-secreting adenoma cells from patients classified as both fully and only partially responsive to the currently used SRIF analogs, octreotide and lanreotide, and without formation of an interfering metabolite. The gene discussed is GH1; the disease is adenoma.